Merck Serono and ZymoGenetics restructure atacicept deal

Merck Serono, the biopharmaceutical division ofMerck KGaA, and ZymoGenetics have restructured their agreement covering the development of atacicept for the treatment of various autoimmune and B-cell malignancies.